MS News That Caught My Eye Last Week: Global MS Numbers, Pregnancy and MS, ANK-700

MS News That Caught My Eye Last Week: Global MS Numbers, Pregnancy and MS, ANK-700
4.3
(9)

MS Prevalence at Over 2.8 Million Worldwide, Update to Atlas Reports

With almost 3 million of us around the world, we’re not really rare, but we’re rare enough that our MS is still a puzzle to many. People seem to know what muscular dystrophy is (probably because of the annual telethon in past years), and they know about cancer and heart disease. Why don’t they know about MS? We need to do more to promote MS awareness, wouldn’t you agree?

More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1 million in the United States, an update to the Atlas of MS reports.

An increase since its previous update, this number translates to someone, somewhere in the world, being newly diagnosed with the disease every five minutes, the National MS Society announced in a press release on the update.

Click here to read the full story.

***

Pregnancy Delays Likely MS Onset by About 3 Years, Large Study Finds

How MS affects pregnancy is a question I see asked regularly in social media groups. This study may help to partially answer that question. It reports that pregnancy may delay the onset of MS symptoms. Other studies have reported that a woman has fewer relapses while pregnant. 

After a pregnancy or childbirth, most women who went on to develop clinically isolated syndrome (CIS) did so about three years later than those who were never pregnant, a large and multicenter study reported.

Multiple pregnancies or births, however, were not seen to further affect CIS onset.

Click here to read the full story.

***

Anokion Planning Launch of Phase 1 Trial of Investigational MS Therapy ANK-700

We know that with MS, our immune system attacks parts of our body that it shouldn’t attack. This investigational medication is designed to “reeducate” the immune system of people with MS so that it understands it shouldn’t attack healthy cells. Those at the company Anokion hope to begin a Phase 1 trial at several locations by the end of the year.

The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700, a treatment candidate for multiple sclerosis (MS) that is being developed by the Swiss company Anokion.

With this approval, Anokion can enter clinical testing and is planning to initiate a multicenter, Phase 1 clinical trial to evaluate ANK-700 in people with MS by the end of the year.

Click here to read the full story.

***

 Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.
×
Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

How useful was this post?

Click on a star to rate it!

Average rating 4.3 / 5. Vote count: 9

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *